Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...

Initially, macular telangiectasia (MacTel) type 2 was considered a retinal vascular disease; however, over the past decade, studies have revealed that it is in fact a neurodegenerative condition ...

The introduction of anti-VEGF agents has revolutionized the field of medical retina care by reducing rates of vision loss and ...

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...

Compared with sham, patients implanted with NT-501 (revakinagene taroretcel, Neurotech Pharmaceuticals) for macular telangiectasia (MacTel) experienced less ellipsoid zone loss, a reduction in the ...

001). PDUFA date: March 18, 2025. Macular telangiectasia type 2 (MacTel) is a rare, progressive eye disease that affects the macula and causes a gradual deterioration in central vision.